Intravenous Anesthetics for the Treatment of Chronic Pain and Psychiatric Disorders
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs coverage determinations for IV infusions of anesthetics (for example, ketamine and lidocaine) used to treat chronic pain syndromes and certain psychiatric disorders for Blue Cross Blue Shield - Rhode Island members.
No material clinical or coverage changes in this revision.
Coverage Determinations
Not covered / Not medically necessary
Coverage determinations
applies to Medicare Advantage plans
applies to Medicare Advantage plans
applies to Commercial products
applies to Commercial products
The policy identifies the use of intravenous anesthetics outside their FDA‑approved indications: IV lidocaine is FDA‑approved for systemic use in the acute treatment of arrhythmias and for local anesthesia, and IV ketamine is FDA‑approved for anesthesia-related indications. Use of IV lidocaine or IV ketamine for chronic pain or for psychiatric disorders (for example, chronic neuropathic pain, chronic daily headache, fibromyalgia, treatment‑resistant depression, obsessive‑compulsive disorder, or posttraumatic stress disorder) is considered off‑label per this policy.
Services that are determined by Blue Cross & Blue Shield of Rhode Island to be not medically necessary, or services that are identified as non‑covered benefits under the member’s subscriber agreement or employer agreement, may be excluded from coverage. Providers should refer to the member’s Evidence of Coverage or subscriber agreement for benefit specifics and contact the provider call center for member‑specific eligibility and benefit information.
For Commercial products, intravenous infusion of anesthetics (eg, ketamine or lidocaine) for the treatment of chronic pain or psychiatric disorders is considered not medically necessary. The policy states the evidence is insufficient to determine effects on health outcomes for these indications.
Treatments determined by BCBSRI to be not medically necessary are not covered and may lead to claim denial. Providers may not bill the member for such services unless the member has been informed and has provided written agreement in advance to continue the treatment at their own expense; refer to participation and subscriber agreements for applicable provisions.
Coding and Billing Guidance
| unlisted HCPCS | No specific HCPCS code(s); use unlisted HCPCS drug code(s) for these treatments |
| unlisted HCPCS | There is no specific HCPCS code(s) for this service; claims should be filed using an unlisted HCPCS drug code(s) for the treatments noted in this policy. |
Provider Actions and Billing Instructions
Prior authorization requirement
Prior authorization: Not applicable.
- The policy explicitly states "Not applicable" under PRIOR AUTHORIZATION.
Verify benefits and prior authorization; claims filing guidance
Verify member benefits and any prior authorization requirements with BCBSRI before providing services; file claims using an unlisted HCPCS drug code as there is no specific HCPCS code for these treatments.
- For member-specific benefits call the provider call center (benefits and eligibility are determined by subscriber/employer agreement).
- Claims should be filed using an unlisted HCPCS drug code.
Confirm member benefits via Evidence of Coverage/Subscriber Agreement
Benefits may vary between groups/contracts; refer to the member's Evidence of Coverage or Subscriber Agreement for applicable coverage determinations.
- Evidence of Coverage or Subscriber Agreement supersedes this medical policy for member-specific benefits.
Provider action: verify and document member eligibility
Confirm member eligibility and benefits with BCBSRI and document the verification in the medical record prior to service delivery.
- Use the provider call center for member-specific benefit details.
- Document benefit/eligibility verification in the chart.
Use unlisted HCPCS drug code(s) for billing
No specific HCPCS code exists for intravenous anesthetic infusions in this policy; submit claims using an appropriate unlisted HCPCS drug code.
- "There is no specific HCPCS code(s) for this service; Claims should be filed using an unlisted HCPCS drug code(s) for the treatments noted in this policy."
Claims submission and benefit verification
Submit claims using an unlisted HCPCS drug code and verify member-specific benefits and eligibility via the provider call center or subscriber agreement, which supersede this policy.
- Claims should be filed with an unlisted HCPCS drug code for intravenous anesthetic treatments.
- For member-specific benefits, call the provider call center; subscriber/employer agreement supersedes policy.
Coverage denial risk for IV anesthetic infusions
For Medicare Advantage plans and Commercial products, IV infusion of anesthetics (e.g., ketamine or lidocaine) for chronic pain or psychiatric disorders is not covered or is considered not medically necessary and may be denied.
- Medicare Advantage: "Intravenous infusion of anesthetics... is not covered."
- Commercial: "Intravenous infusion of anesthetics... is considered not medically necessary."
Risk of claim denial if not medically necessary or non-covered
Claims may be denied when services are determined to be not medically necessary or are non-covered benefits; verify eligibility and benefits before providing services.
- "If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member..."
- Benefits and eligibility are determined by the member's subscriber agreement or employer agreement. Call the provider call center for member-specific benefits.
Background and Evidence Summary
Intravenous lidocaine and ketamine have been investigated in the literature for a range of chronic pain syndromes (including chronic neuropathic pain, chronic daily headache, and fibromyalgia) and for psychiatric disorders (for example, treatment‑resistant depression, obsessive‑compulsive disorder, and posttraumatic stress disorder). Published protocols vary but commonly use subanesthetic dosing delivered via infusions over periods ranging from about 1–6 hours, repeated over days in some series. Available trials demonstrate variable quality and report limited or short‑term benefits in some settings, raising concerns about the durability of effect and adverse events; consequently, BCBSRI considers these indications either not covered (Medicare Advantage) or not medically necessary (Commercial) due to insufficient evidence of improved health outcomes.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.